Global Hepatitis B Vaccines Market to Reach $3.4 Billion by 2027

ReportLinker
ReportLinker

In the changed post COVID-19 business landscape, the global market for Hepatitis B Vaccines estimated at US$2. 6 Billion in the year 2020, is projected to reach a revised size of US$3. 4 Billion by 2027, growing at aCAGR of 3.

New York, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Hepatitis B Vaccines Industry" - https://www.reportlinker.com/p06041565/?utm_source=GNW
9% over the period 2020-2027. Combination Vaccines, one of the segments analyzed in the report, is projected to record 4.4% CAGR and reach US$2.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Mono Vaccines segment is readjusted to a revised 3.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $715.6 Million, While China is Forecast to Grow at 6.5% CAGR

The Hepatitis B Vaccines market in the U.S. is estimated at US$715.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$668.6 Million by the year 2027 trailing a CAGR of 6.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.1% and 3.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Select Competitors (Total 14 Featured) -
Beijing Minhai Biotechnology Co., Ltd.
Bharat Biotech International Ltd.
Binnopharm Group LLC
Biokangtai
CSL Ltd.
Dynavax Technologies Corporation
Emergent BioSolutions, Inc.
GlaxoSmithKline PLC
Hualan Biological Engineering Co., Ltd.
Merck & Co., Inc.


Read the full report: https://www.reportlinker.com/p06041565/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
Hepatitis B Vaccines - Global Key Competitors Percentage Market
Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Hepatitis B Vaccines Market Analysis of Annual
Sales in US$ Million for Years 2012 through 2027

Table 2: World Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 3: World Historic Review for Hepatitis B Vaccines by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 4: World 15-Year Perspective for Hepatitis B Vaccines by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2021 & 2027

Table 5: World Recent Past, Current & Future Analysis for
Combination Vaccines by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 6: World Historic Review for Combination Vaccines by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 7: World 15-Year Perspective for Combination Vaccines by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 8: World Recent Past, Current & Future Analysis for Mono
Vaccines by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 9: World Historic Review for Mono Vaccines by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 10: World 15-Year Perspective for Mono Vaccines by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 11: World Recent Past, Current & Future Analysis for
Adult by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 12: World Historic Review for Adult by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 13: World 15-Year Perspective for Adult by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 14: World Recent Past, Current & Future Analysis for
Pediatric by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 15: World Historic Review for Pediatric by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 16: World 15-Year Perspective for Pediatric by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 17: World Recent Past, Current & Future Analysis for
Hospitals by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 18: World Historic Review for Hospitals by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 19: World 15-Year Perspective for Hospitals by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 20: World Recent Past, Current & Future Analysis for
Clinics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 21: World Historic Review for Clinics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 22: World 15-Year Perspective for Clinics by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 23: World Recent Past, Current & Future Analysis for
Other End-Uses by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 24: World Historic Review for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 25: World 15-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES
Hepatitis B Vaccines Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United States for 2022 (E)
Table 26: USA Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Type - Combination Vaccines and Mono
Vaccines - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 27: USA Historic Review for Hepatitis B Vaccines by Type -
Combination Vaccines and Mono Vaccines Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 28: USA 15-Year Perspective for Hepatitis B Vaccines by
Type - Percentage Breakdown of Value Sales for Combination
Vaccines and Mono Vaccines for the Years 2012, 2021 & 2027

Table 29: USA Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Application - Adult and Pediatric -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 30: USA Historic Review for Hepatitis B Vaccines by
Application - Adult and Pediatric Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 31: USA 15-Year Perspective for Hepatitis B Vaccines by
Application - Percentage Breakdown of Value Sales for Adult and
Pediatric for the Years 2012, 2021 & 2027

Table 32: USA Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other
End-Uses - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 33: USA Historic Review for Hepatitis B Vaccines by
End-Use - Hospitals, Clinics and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 34: USA 15-Year Perspective for Hepatitis B Vaccines by
End-Use - Percentage Breakdown of Value Sales for Hospitals,
Clinics and Other End-Uses for the Years 2012, 2021 & 2027

CANADA
Table 35: Canada Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Type - Combination Vaccines and Mono
Vaccines - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 36: Canada Historic Review for Hepatitis B Vaccines by
Type - Combination Vaccines and Mono Vaccines Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 37: Canada 15-Year Perspective for Hepatitis B Vaccines
by Type - Percentage Breakdown of Value Sales for Combination
Vaccines and Mono Vaccines for the Years 2012, 2021 & 2027

Table 38: Canada Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Application - Adult and Pediatric -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 39: Canada Historic Review for Hepatitis B Vaccines by
Application - Adult and Pediatric Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 40: Canada 15-Year Perspective for Hepatitis B Vaccines
by Application - Percentage Breakdown of Value Sales for Adult
and Pediatric for the Years 2012, 2021 & 2027

Table 41: Canada Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other
End-Uses - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 42: Canada Historic Review for Hepatitis B Vaccines by
End-Use - Hospitals, Clinics and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 43: Canada 15-Year Perspective for Hepatitis B Vaccines
by End-Use - Percentage Breakdown of Value Sales for Hospitals,
Clinics and Other End-Uses for the Years 2012, 2021 & 2027

JAPAN
Hepatitis B Vaccines Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Japan for 2022 (E)
Table 44: Japan Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Type - Combination Vaccines and Mono
Vaccines - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 45: Japan Historic Review for Hepatitis B Vaccines by
Type - Combination Vaccines and Mono Vaccines Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 46: Japan 15-Year Perspective for Hepatitis B Vaccines by
Type - Percentage Breakdown of Value Sales for Combination
Vaccines and Mono Vaccines for the Years 2012, 2021 & 2027

Table 47: Japan Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Application - Adult and Pediatric -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 48: Japan Historic Review for Hepatitis B Vaccines by
Application - Adult and Pediatric Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 49: Japan 15-Year Perspective for Hepatitis B Vaccines by
Application - Percentage Breakdown of Value Sales for Adult and
Pediatric for the Years 2012, 2021 & 2027

Table 50: Japan Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other
End-Uses - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 51: Japan Historic Review for Hepatitis B Vaccines by
End-Use - Hospitals, Clinics and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 52: Japan 15-Year Perspective for Hepatitis B Vaccines by
End-Use - Percentage Breakdown of Value Sales for Hospitals,
Clinics and Other End-Uses for the Years 2012, 2021 & 2027

CHINA
Hepatitis B Vaccines Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in China for 2022 (E)
Table 53: China Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Type - Combination Vaccines and Mono
Vaccines - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 54: China Historic Review for Hepatitis B Vaccines by
Type - Combination Vaccines and Mono Vaccines Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 55: China 15-Year Perspective for Hepatitis B Vaccines by
Type - Percentage Breakdown of Value Sales for Combination
Vaccines and Mono Vaccines for the Years 2012, 2021 & 2027

Table 56: China Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Application - Adult and Pediatric -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 57: China Historic Review for Hepatitis B Vaccines by
Application - Adult and Pediatric Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 58: China 15-Year Perspective for Hepatitis B Vaccines by
Application - Percentage Breakdown of Value Sales for Adult and
Pediatric for the Years 2012, 2021 & 2027

Table 59: China Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other
End-Uses - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 60: China Historic Review for Hepatitis B Vaccines by
End-Use - Hospitals, Clinics and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 61: China 15-Year Perspective for Hepatitis B Vaccines by
End-Use - Percentage Breakdown of Value Sales for Hospitals,
Clinics and Other End-Uses for the Years 2012, 2021 & 2027

EUROPE
Hepatitis B Vaccines Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Europe for 2022 (E)
Table 62: Europe Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 63: Europe Historic Review for Hepatitis B Vaccines by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 64: Europe 15-Year Perspective for Hepatitis B Vaccines
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2021 & 2027

Table 65: Europe Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Type - Combination Vaccines and Mono
Vaccines - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 66: Europe Historic Review for Hepatitis B Vaccines by
Type - Combination Vaccines and Mono Vaccines Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 67: Europe 15-Year Perspective for Hepatitis B Vaccines
by Type - Percentage Breakdown of Value Sales for Combination
Vaccines and Mono Vaccines for the Years 2012, 2021 & 2027

Table 68: Europe Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Application - Adult and Pediatric -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 69: Europe Historic Review for Hepatitis B Vaccines by
Application - Adult and Pediatric Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 70: Europe 15-Year Perspective for Hepatitis B Vaccines
by Application - Percentage Breakdown of Value Sales for Adult
and Pediatric for the Years 2012, 2021 & 2027

Table 71: Europe Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other
End-Uses - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 72: Europe Historic Review for Hepatitis B Vaccines by
End-Use - Hospitals, Clinics and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 73: Europe 15-Year Perspective for Hepatitis B Vaccines
by End-Use - Percentage Breakdown of Value Sales for Hospitals,
Clinics and Other End-Uses for the Years 2012, 2021 & 2027

FRANCE
Hepatitis B Vaccines Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in France for 2022 (E)
Table 74: France Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Type - Combination Vaccines and Mono
Vaccines - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 75: France Historic Review for Hepatitis B Vaccines by
Type - Combination Vaccines and Mono Vaccines Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 76: France 15-Year Perspective for Hepatitis B Vaccines
by Type - Percentage Breakdown of Value Sales for Combination
Vaccines and Mono Vaccines for the Years 2012, 2021 & 2027

Table 77: France Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Application - Adult and Pediatric -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 78: France Historic Review for Hepatitis B Vaccines by
Application - Adult and Pediatric Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 79: France 15-Year Perspective for Hepatitis B Vaccines
by Application - Percentage Breakdown of Value Sales for Adult
and Pediatric for the Years 2012, 2021 & 2027

Table 80: France Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other
End-Uses - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 81: France Historic Review for Hepatitis B Vaccines by
End-Use - Hospitals, Clinics and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 82: France 15-Year Perspective for Hepatitis B Vaccines
by End-Use - Percentage Breakdown of Value Sales for Hospitals,
Clinics and Other End-Uses for the Years 2012, 2021 & 2027

GERMANY
Hepatitis B Vaccines Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Germany for 2022 (E)
Table 83: Germany Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Type - Combination Vaccines and Mono
Vaccines - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 84: Germany Historic Review for Hepatitis B Vaccines by
Type - Combination Vaccines and Mono Vaccines Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 85: Germany 15-Year Perspective for Hepatitis B Vaccines
by Type - Percentage Breakdown of Value Sales for Combination
Vaccines and Mono Vaccines for the Years 2012, 2021 & 2027

Table 86: Germany Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Application - Adult and Pediatric -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 87: Germany Historic Review for Hepatitis B Vaccines by
Application - Adult and Pediatric Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 88: Germany 15-Year Perspective for Hepatitis B Vaccines
by Application - Percentage Breakdown of Value Sales for Adult
and Pediatric for the Years 2012, 2021 & 2027

Table 89: Germany Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other
End-Uses - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 90: Germany Historic Review for Hepatitis B Vaccines by
End-Use - Hospitals, Clinics and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 91: Germany 15-Year Perspective for Hepatitis B Vaccines
by End-Use - Percentage Breakdown of Value Sales for Hospitals,
Clinics and Other End-Uses for the Years 2012, 2021 & 2027

ITALY
Table 92: Italy Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Type - Combination Vaccines and Mono
Vaccines - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 93: Italy Historic Review for Hepatitis B Vaccines by
Type - Combination Vaccines and Mono Vaccines Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 94: Italy 15-Year Perspective for Hepatitis B Vaccines by
Type - Percentage Breakdown of Value Sales for Combination
Vaccines and Mono Vaccines for the Years 2012, 2021 & 2027

Table 95: Italy Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Application - Adult and Pediatric -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 96: Italy Historic Review for Hepatitis B Vaccines by
Application - Adult and Pediatric Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 97: Italy 15-Year Perspective for Hepatitis B Vaccines by
Application - Percentage Breakdown of Value Sales for Adult and
Pediatric for the Years 2012, 2021 & 2027

Table 98: Italy Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other
End-Uses - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 99: Italy Historic Review for Hepatitis B Vaccines by
End-Use - Hospitals, Clinics and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 100: Italy 15-Year Perspective for Hepatitis B Vaccines
by End-Use - Percentage Breakdown of Value Sales for Hospitals,
Clinics and Other End-Uses for the Years 2012, 2021 & 2027

UNITED KINGDOM
Hepatitis B Vaccines Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United Kingdom for 2022 (E)
Table 101: UK Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Type - Combination Vaccines and Mono
Vaccines - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 102: UK Historic Review for Hepatitis B Vaccines by Type -
Combination Vaccines and Mono Vaccines Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 103: UK 15-Year Perspective for Hepatitis B Vaccines by
Type - Percentage Breakdown of Value Sales for Combination
Vaccines and Mono Vaccines for the Years 2012, 2021 & 2027

Table 104: UK Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Application - Adult and Pediatric -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 105: UK Historic Review for Hepatitis B Vaccines by
Application - Adult and Pediatric Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 106: UK 15-Year Perspective for Hepatitis B Vaccines by
Application - Percentage Breakdown of Value Sales for Adult and
Pediatric for the Years 2012, 2021 & 2027

Table 107: UK Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other
End-Uses - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 108: UK Historic Review for Hepatitis B Vaccines by
End-Use - Hospitals, Clinics and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 109: UK 15-Year Perspective for Hepatitis B Vaccines by
End-Use - Percentage Breakdown of Value Sales for Hospitals,
Clinics and Other End-Uses for the Years 2012, 2021 & 2027

SPAIN
Table 110: Spain Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Type - Combination Vaccines and Mono
Vaccines - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 111: Spain Historic Review for Hepatitis B Vaccines by
Type - Combination Vaccines and Mono Vaccines Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 112: Spain 15-Year Perspective for Hepatitis B Vaccines
by Type - Percentage Breakdown of Value Sales for Combination
Vaccines and Mono Vaccines for the Years 2012, 2021 & 2027

Table 113: Spain Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Application - Adult and Pediatric -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 114: Spain Historic Review for Hepatitis B Vaccines by
Application - Adult and Pediatric Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 115: Spain 15-Year Perspective for Hepatitis B Vaccines
by Application - Percentage Breakdown of Value Sales for Adult
and Pediatric for the Years 2012, 2021 & 2027

Table 116: Spain Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other
End-Uses - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 117: Spain Historic Review for Hepatitis B Vaccines by
End-Use - Hospitals, Clinics and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 118: Spain 15-Year Perspective for Hepatitis B Vaccines
by End-Use - Percentage Breakdown of Value Sales for Hospitals,
Clinics and Other End-Uses for the Years 2012, 2021 & 2027

RUSSIA
Table 119: Russia Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Type - Combination Vaccines and Mono
Vaccines - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 120: Russia Historic Review for Hepatitis B Vaccines by
Type - Combination Vaccines and Mono Vaccines Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 121: Russia 15-Year Perspective for Hepatitis B Vaccines
by Type - Percentage Breakdown of Value Sales for Combination
Vaccines and Mono Vaccines for the Years 2012, 2021 & 2027

Table 122: Russia Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by Application - Adult and Pediatric -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 123: Russia Historic Review for Hepatitis B Vaccines by
Application - Adult and Pediatric Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 124: Russia 15-Year Perspective for Hepatitis B Vaccines
by Application - Percentage Breakdown of Value Sales for Adult
and Pediatric for the Years 2012, 2021 & 2027

Table 125: Russia Recent Past, Current & Future Analysis for
Hepatitis B Vaccines by End-Use - Hospitals, Clinics and Other
End-Uses - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 126: Russia Historic Review for Hepatitis B Vaccines by
End-Use - Hospitals, Clinics and Other End-Uses Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 127: Russia 15-Year Perspective for Hepatitis B Vaccines
by End-Use - Percentage Breakdown of Value Sales for Hospitals,
Clinics and Other End-Uses for the Years 2012, 2021 & 2027

REST OF EUROPE
Table 128: Rest of Europe Recent Past, Current & Future
Analysis for Hepatitis B Vaccines by Type - Combination
Vaccines and Mono Vaccines - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 129: Rest of Europe Historic Review for Hepatitis B
Vaccines by Type - Combination Vaccines and Mono Vaccines
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 130: Rest of Europe 15-Year Perspective for Hepatitis B
Vaccines by Type - Percentage Breakdown of Value Sales for
Combination Vaccines and Mono Vaccines for the Years 2012, 2021 &
2027

Table 131: Rest of Europe Recent Past, Current & Future
Analysis for Hepatitis B Vaccines by Application - Adult and
Pediatric - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 132: Rest of Europe Historic Review for Hepatitis B
Vaccines by Application - Adult and Pediatric Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 133: Rest of Europe 15-Year Perspective for Hepatitis B
Vaccines by Application - Percentage Breakdown of Value Sales
for Adult and Pediatric for the Years 2012, 2021 & 2027

Table 134: Rest of Europe Recent Past, Current & Future
Analysis for Hepatitis B Vaccines by End-Use - Hospitals,
Clinics and Other End-Uses - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 135: Rest of Europe Historic Review for Hepatitis B
Vaccines by End-Use - Hospitals, Clinics and Other End-Uses
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 136: Rest of Europe 15-Year Perspective for Hepatitis B
Vaccines by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Other End-Uses for the Years 2012, 2021 &
2027

ASIA-PACIFIC
Hepatitis B Vaccines Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Asia-Pacific for 2022 (E)
Table 137: Asia-Pacific Recent Past, Current & Future Analysis
for Hepatitis B Vaccines by Geographic Region - Australia,
India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 138: Asia-Pacific Historic Review for Hepatitis B
Vaccines by Geographic Region - Australia, India, South Korea
and Rest of Asia-Pacific Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 139: Asia-Pacific 15-Year Perspective for Hepatitis B
Vaccines by Geographic Region - Percentage Breakdown of Value
Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2012, 2021 & 2027

Table 140: Asia-Pacific Recent Past, Current & Future Analysis
for Hepatitis B Vaccines by Type - Combination Vaccines and
Mono Vaccines - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 141: Asia-Pacific Historic Review for Hepatitis B

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06041565/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001